Sage Therapeutics and Biogen End Collaboration on SAGE-324 Program
    Sage Therapeutics and Biogen End Collaboration on SAGE-324 Program
    PRISM Biotech

    September 26, 2024 - by Alex Corbit

    Sage Therapeutics and Biogen End Collaboration on SAGE-324 Program

    26 September 2024

    New York, September 26, 2024 - PRISM MarketView - Sage Therapeutics, Inc. (NASDAQ: SAGE) announced the discontinuation of its collaboration with Biogen Inc. (NASDAQ: BIIB) on the SAGE-324 program following recent negative Phase 2 trial results. Despite this, the companies will continue their partnership on ZURZUVAE®, the first FDA-approved oral treatment for postpartum depression (PPD).
    Sage Therapeutics, Inc. - Prism MarketView

    Sage Therapeutics, Inc. - Prism MarketView

    Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating d

    Read More

    Key Highlights:
    • Discontinuation of SAGE-324 Program: Biogen has terminated its rights under the collaboration agreement with Sage specific to SAGE-324. This decision follows the negative results of the Phase 2 KINETIC 2 study for the treatment of essential tremor (ET).
    • Effective Termination: The collaboration and license agreement will end on February 17, 2025, with Sage resuming full ownership of the SAGE-324 asset.
    • Potential Future Evaluation: Sage plans to assess other potential indications for SAGE-324, if any, despite the discontinuation in ET.
    • Continuing Partnership on ZURZUVAE®: Sage and Biogen will maintain their collaboration on ZURZUVAE®, continuing their efforts to support women with postpartum depression.
    About Sage Therapeutics
    Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.